Synthesis, antimicrobial evaluation and in silico studies of novel 2,4-disubstituted-1,3-thiazole derivatives

Mir Mohammad Masood, Mohammad Irfan, Shadab Alam, Phool Hasan, Aarfa Queen, Shifa Shahid, Muhammad Zahid, Amir Azam, Mohammad Abid

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: 2,4-disubstituted-1,3-thiazole derivatives (2a–j), (3a–f) and (4a–f) were synthesized, characterized and screened for their potential as antimicrobial agents. In the preliminary screening against a panel of bacterial strains, nine compounds showed moderate to potent antibacterial activity (IC 50 = 13.7-90.8 µg/ml). Methods: In the antifungal screening, compound (4c) displayed potent antifungal activity (IC 50 = 26.5 µg/ml) against Candida tropicalis comparable to the standard drug, fluconazole (IC 50 = 10.5 µg/ml). Based on in vitro antimicrobial results, compounds 2f, 4c and 4e were selected for further pharmacological investigations. Hemolytic activity using human red blood cells (hRBCs) and cytotoxicity by MTT assay on human embryonic kidney (HEK-293) cells revealed non-toxic nature of the selected compounds (2f, 4c and 4e). To ascertain their possible mode of action, docking studies with the lead inhibitors (2f, 4c and 4e) were performed using crystal structure coordinates of bacterial methionine aminopeptidases (MetAPs), an enzyme involved in bacterial protein synthesis and maturation. Results: The results of in vitro and in silico studies provide a rationale for selected compounds (2f, 4c and 4e) to be carried forward for further structural modifications and structure-activity relationship (SAR) studies against these bacterial infections. Conclusion: The study suggested binding with one or more key amino acid residues in the active site of Streptococcus pneumoniae MetAP (SpMetAP) and Escherichia coli MetAP (EcMetAP). In silico physicochemical properties using QikProp confirmed their drug likeliness.

Original languageEnglish (US)
Pages (from-to)160-173
Number of pages14
JournalLetters in Drug Design and Discovery
Volume16
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Thiazoles
Computer Simulation
Candida tropicalis
Bacterial Structures
Aminopeptidases
Bacterial Proteins
Fluconazole
HEK293 Cells
Structure-Activity Relationship
Anti-Infective Agents
Streptococcus pneumoniae
Bacterial Infections
Human Activities
Pharmaceutical Preparations
Methionine
Catalytic Domain
Erythrocytes
Pharmacology
Escherichia coli
Kidney

Keywords

  • 2,4-disubstituted-1,3-thiazole
  • ADME
  • Antimicrobial
  • Cytotoxicity
  • Docking
  • Hemolysis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Synthesis, antimicrobial evaluation and in silico studies of novel 2,4-disubstituted-1,3-thiazole derivatives. / Masood, Mir Mohammad; Irfan, Mohammad; Alam, Shadab; Hasan, Phool; Queen, Aarfa; Shahid, Shifa; Zahid, Muhammad; Azam, Amir; Abid, Mohammad.

In: Letters in Drug Design and Discovery, Vol. 16, No. 2, 01.01.2018, p. 160-173.

Research output: Contribution to journalArticle

Masood, Mir Mohammad ; Irfan, Mohammad ; Alam, Shadab ; Hasan, Phool ; Queen, Aarfa ; Shahid, Shifa ; Zahid, Muhammad ; Azam, Amir ; Abid, Mohammad. / Synthesis, antimicrobial evaluation and in silico studies of novel 2,4-disubstituted-1,3-thiazole derivatives. In: Letters in Drug Design and Discovery. 2018 ; Vol. 16, No. 2. pp. 160-173.
@article{28fea95ecfdc4794a4501140628eab13,
title = "Synthesis, antimicrobial evaluation and in silico studies of novel 2,4-disubstituted-1,3-thiazole derivatives",
abstract = "Background: 2,4-disubstituted-1,3-thiazole derivatives (2a–j), (3a–f) and (4a–f) were synthesized, characterized and screened for their potential as antimicrobial agents. In the preliminary screening against a panel of bacterial strains, nine compounds showed moderate to potent antibacterial activity (IC 50 = 13.7-90.8 µg/ml). Methods: In the antifungal screening, compound (4c) displayed potent antifungal activity (IC 50 = 26.5 µg/ml) against Candida tropicalis comparable to the standard drug, fluconazole (IC 50 = 10.5 µg/ml). Based on in vitro antimicrobial results, compounds 2f, 4c and 4e were selected for further pharmacological investigations. Hemolytic activity using human red blood cells (hRBCs) and cytotoxicity by MTT assay on human embryonic kidney (HEK-293) cells revealed non-toxic nature of the selected compounds (2f, 4c and 4e). To ascertain their possible mode of action, docking studies with the lead inhibitors (2f, 4c and 4e) were performed using crystal structure coordinates of bacterial methionine aminopeptidases (MetAPs), an enzyme involved in bacterial protein synthesis and maturation. Results: The results of in vitro and in silico studies provide a rationale for selected compounds (2f, 4c and 4e) to be carried forward for further structural modifications and structure-activity relationship (SAR) studies against these bacterial infections. Conclusion: The study suggested binding with one or more key amino acid residues in the active site of Streptococcus pneumoniae MetAP (SpMetAP) and Escherichia coli MetAP (EcMetAP). In silico physicochemical properties using QikProp confirmed their drug likeliness.",
keywords = "2,4-disubstituted-1,3-thiazole, ADME, Antimicrobial, Cytotoxicity, Docking, Hemolysis",
author = "Masood, {Mir Mohammad} and Mohammad Irfan and Shadab Alam and Phool Hasan and Aarfa Queen and Shifa Shahid and Muhammad Zahid and Amir Azam and Mohammad Abid",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570180815666180502120042",
language = "English (US)",
volume = "16",
pages = "160--173",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Synthesis, antimicrobial evaluation and in silico studies of novel 2,4-disubstituted-1,3-thiazole derivatives

AU - Masood, Mir Mohammad

AU - Irfan, Mohammad

AU - Alam, Shadab

AU - Hasan, Phool

AU - Queen, Aarfa

AU - Shahid, Shifa

AU - Zahid, Muhammad

AU - Azam, Amir

AU - Abid, Mohammad

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: 2,4-disubstituted-1,3-thiazole derivatives (2a–j), (3a–f) and (4a–f) were synthesized, characterized and screened for their potential as antimicrobial agents. In the preliminary screening against a panel of bacterial strains, nine compounds showed moderate to potent antibacterial activity (IC 50 = 13.7-90.8 µg/ml). Methods: In the antifungal screening, compound (4c) displayed potent antifungal activity (IC 50 = 26.5 µg/ml) against Candida tropicalis comparable to the standard drug, fluconazole (IC 50 = 10.5 µg/ml). Based on in vitro antimicrobial results, compounds 2f, 4c and 4e were selected for further pharmacological investigations. Hemolytic activity using human red blood cells (hRBCs) and cytotoxicity by MTT assay on human embryonic kidney (HEK-293) cells revealed non-toxic nature of the selected compounds (2f, 4c and 4e). To ascertain their possible mode of action, docking studies with the lead inhibitors (2f, 4c and 4e) were performed using crystal structure coordinates of bacterial methionine aminopeptidases (MetAPs), an enzyme involved in bacterial protein synthesis and maturation. Results: The results of in vitro and in silico studies provide a rationale for selected compounds (2f, 4c and 4e) to be carried forward for further structural modifications and structure-activity relationship (SAR) studies against these bacterial infections. Conclusion: The study suggested binding with one or more key amino acid residues in the active site of Streptococcus pneumoniae MetAP (SpMetAP) and Escherichia coli MetAP (EcMetAP). In silico physicochemical properties using QikProp confirmed their drug likeliness.

AB - Background: 2,4-disubstituted-1,3-thiazole derivatives (2a–j), (3a–f) and (4a–f) were synthesized, characterized and screened for their potential as antimicrobial agents. In the preliminary screening against a panel of bacterial strains, nine compounds showed moderate to potent antibacterial activity (IC 50 = 13.7-90.8 µg/ml). Methods: In the antifungal screening, compound (4c) displayed potent antifungal activity (IC 50 = 26.5 µg/ml) against Candida tropicalis comparable to the standard drug, fluconazole (IC 50 = 10.5 µg/ml). Based on in vitro antimicrobial results, compounds 2f, 4c and 4e were selected for further pharmacological investigations. Hemolytic activity using human red blood cells (hRBCs) and cytotoxicity by MTT assay on human embryonic kidney (HEK-293) cells revealed non-toxic nature of the selected compounds (2f, 4c and 4e). To ascertain their possible mode of action, docking studies with the lead inhibitors (2f, 4c and 4e) were performed using crystal structure coordinates of bacterial methionine aminopeptidases (MetAPs), an enzyme involved in bacterial protein synthesis and maturation. Results: The results of in vitro and in silico studies provide a rationale for selected compounds (2f, 4c and 4e) to be carried forward for further structural modifications and structure-activity relationship (SAR) studies against these bacterial infections. Conclusion: The study suggested binding with one or more key amino acid residues in the active site of Streptococcus pneumoniae MetAP (SpMetAP) and Escherichia coli MetAP (EcMetAP). In silico physicochemical properties using QikProp confirmed their drug likeliness.

KW - 2,4-disubstituted-1,3-thiazole

KW - ADME

KW - Antimicrobial

KW - Cytotoxicity

KW - Docking

KW - Hemolysis

UR - http://www.scopus.com/inward/record.url?scp=85057755776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057755776&partnerID=8YFLogxK

U2 - 10.2174/1570180815666180502120042

DO - 10.2174/1570180815666180502120042

M3 - Article

AN - SCOPUS:85057755776

VL - 16

SP - 160

EP - 173

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 2

ER -